Generic heart drug shows promise in early comparison study
NCT ID NCT07396519
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a generic version of dronedarone hydrochloride (400 mg tablets) works the same as the brand-name drug MULTAQ in 48 healthy Chinese adults. Participants took a single dose under fed conditions, and researchers measured drug levels in the blood to check for bioequivalence. The goal was to see if the generic can be a safe, affordable alternative for people with atrial fibrillation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dronedarone hydrochloride (generic version of MULTAQ)
What this could lead to
If successful, this could help confirm that a lower-cost generic version of dronedarone is as effective as the brand-name drug for treating atrial fibrillation.
What could go wrong
This is a small, early-stage bioequivalence study in healthy volunteers, not patients. It does not test whether the drug actually treats atrial fibrillation or improves outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangxi Cancer Hospital ＆ Institute (The Second Affiliated Hospital of Nanchang Medical College)
Nanchang, Jiangxi, 330029, China